Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma
Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Body Radiation Therapy;   Biological: Tremelimumab
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Not yet recruiting

https://ift.tt/2I8tj2k